ClinicalTrials.gg
CompletedNCT00637572Updated Oct 5, 2017Results posted

Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss

A Phase 2 interventional study of Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL and Megestrol acetate oral suspension 40 mg/mL in HIV Infections, Cachexia and Anorexia, sponsored by Endo Pharmaceuticals. Completed at 12 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 305 studies in HIV Infections with a site in South Africa — 15 open to participants now, 36 under way, 15 of them phase 3. HIV Infections · South Africa.

Enrollment
211th of 267
63 · median 280
Started
2004
with 10 others
Phase 2
54 of 305
none open now
Registered
98th of 305
by date

Among the 305 studies in HIV Infections with a site in South Africa, this one is the 211th largest by enrollment of the 267 interventional ones that give a count, is one of 11 that started in 2004, is one of 54 in phase 2, and was the 98th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 305 studies in HIV Infections with a site in South Africa are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 305 studies in HIV Infections with a site in South Africa, or all of them as a file.
02

Study summary

Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate oral suspension original formulation

03

Conditions studied

  • HIV Infections
  • Cachexia
  • Anorexia
  • AIDS Wasting Syndrome
  • HIV Wasting Syndrome

Keywords

  • Weight loss
  • Cachexia
  • Anorexia
  • Megestrol acetate oral suspension
  • Nanocrystal dispersion
  • Nanocrystal technology
  • Body weight changes
  • AIDS wasting
  • HIV wasting
  • Emaciation
  • Megace ES
  • Megace
  • Treatment Experienced
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of and willing to provide
  • Evidence of infection (either HIV-seropositive, of ≤350/mm3 or other clinically accepted indicator)
  • An unintentional weight loss resulting in a weight 10% less than the lower limit of Ideal Body Weight for frame size, or a recent history of unintentional weight loss of 10% from the subjects baseline
  • Weight losses was clinically associated with AIDS-related wasting and not related to any other disease process
  • Women of had to agree to use effective for the duration of the study and for two weeks after the last dose
  • Clinical laboratory values had to be within normal limits or out-of-range limits must be designated as not (some exceptions per protocol)
  • Able to read and write in the study related documents translated into the primary local language
  • Capable of and willing to return to the clinic regularly for study visits
  • Must have been taking a stable regimen of accepted HIV anti-retroviral treatments for at least two weeks prior to study entry
  • Capable of completing a 3-day food intake diary with instruction
  • Willing to abstain from any illegal or recreational drug substances for the duration of the trial
  • Willing to abstain from taking any other medications or substances known to affect appetite or weight gain (eg, [other than those inhaled for treatment of asthmatic conditions], nutritional supplements [other than vitamins or minerals], dronabinol, recombinant human growth hormone, etc.)

Exclusion criteria

Exclusion Criteria:

  • Weight loss due to factors other than AIDS-related wasting
  • Enrollment in any other clinical trial
  • Lack of access to regular meals
  • Women of could not be pregnant or nursing
  • Clinically severe depression evidenced by a baseline score of 17 or more on the Hamilton Depression Rating Scale (GRID-HAMD-17)
  • Recent evidence of or history of significant psychiatric illness that may have compromised the subject's ability to comply with the study requirements
  • Intractable or frequent vomiting that regularly interfered with eating
  • diarrhea that would have interfered with absorption of foods or medications
  • Clinically significant oral lesions or dental conditions that would have interfered with eating a regular diet
  • History or evidence of thromboembolic events or any first degree relative with a history of thromboembolic events
  • Active AIDS-defining illness or other clinically significant or uncontrolled medical problems
  • Current evidence of or history of diabetes mellitus or hypoadrenalism
  • Systemic treatment with within the 12 months prior to study entry
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Megestrol acetate oral suspension nanocrystal dispersion

    Megestrol acetate oral suspension nanocrystal dispersion formulation 115 mg/mL

    Drug: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL

  • Active comparator
    Megestrol acetate oral suspension micronized formulation

    Megestrol acetate oral suspension micronized formulation 60 mg/mL

    Drug: Megestrol acetate oral suspension 40 mg/mL

Interventions

  • DrugMegestrol acetate oral suspension nanocrystal dispersion 115 mg/mL

    Drug page: Megestrol Acetate

    Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)

    Also known as: Megace ES

  • DrugMegestrol acetate oral suspension 40 mg/mL

    Drug page: Megestrol Acetate

    Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)

    Also known as: Megace

06

What researchers measure

Primary outcomes

  1. Change in Body Weight

    Weight gain in adult HIV positive subjects who have weight loss with AIDS related wasting within the first 12 weeks of treatment

    Time frame: Baseline (Day 1) to Week 12

Secondary outcomes

  1. Change From Baseline in Lean Mass

    Time frame: Baseline (Day 1) to Week 12

  2. Change From Baseline in Impedance

    Electrical impedance is a method for body composition assessment. The procedure involves sending a small current through the body and measuring the resistance in ohm. High resistance is associated with smaller amounts of fat-free mass. Smaller resistance is associated with large amounts of fat-free mass.

    Time frame: Baseline (Day 1) to Week 12

  3. Change From Baseline in Body Fat Mass

    Time frame: Baseline (Day 1) to Week 12

  4. Change in Hip Circumference

    Time frame: Baseline (Day 1) to Week 12

  5. Change in Waist Circumference

    Time frame: Baseline (Day 1) to Week 12

  6. Change in Tricep Skinfold

    Time frame: Baseline (Day 1) to Week 12

  7. Change in Mid-arm Circumference

    Time frame: Baseline (Day 1) to Week 12

  8. Change in Total Energy

    Food intake was quantified by the 24-hour recall food diary

    Time frame: Baseline (Day 1) to Week 12

  9. Quality of Life (QoL) Via Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) at Baseline (Day 3) and Week 12 (BACRI)

    The BACRI instrument is used to measure the benefit of weight gain treatment provided to anorexic patients on health related quality of life aspects. The scale is composed of 9 subscales (0 to 10 \[worse to better\]). The response was captured on a VAS scale in cm. The total BACRI score is the sum with a minimum score 0=worse and maximum score 90=better. These subscales are: change in weight impacting health; concern about weight; appearance change; change feeling of appearance; change in appetite; enjoy eating; overall feeling; benefit of treatment; and quality of life.

    Time frame: Baseline (Day 3) to Week 12

  10. Appetite at Baseline (Day 3) and Week 12

    Appetite was assessed via visual analogue scale (VAS) as part of the Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) (Question 5 only). The question was "To what extent has your appetite changed since the start of treatment?" The response was captured on a VAS scale in cm with a range from 0 ( "much worse") to 10 ("much better").

    Time frame: Baseline (Day 3) to Week 12

07

Results

Posted Apr 20, 2016

Participant flow

Participant flow — Overall Study
MilestoneMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Started3231
Completed2924
Not completed37
Withdrew: Adverse event12
Withdrew: Death01
Withdrew: Lost to follow-up01
Withdrew: Physician decision11
Withdrew: Withdrawal by subject02
Withdrew: Illicit drug use10

Outcome measures

PrimaryChange in Body Weight

Weight gain in adult HIV positive subjects who have weight loss with AIDS related wasting within the first 12 weeks of treatment

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · kg
Change in Body Weight
kgMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Overall5.4 ± 5.323.5 ± 4.03
Male7.0 ± 3.163.5 ± 4.72
Female2.3 ± 7.183.5 ± 3.42
SecondaryChange From Baseline in Lean Mass
Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · kg
Change From Baseline in Lean Mass
kgMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Change From Baseline in Lean Mass2.1 ± 3.741.3 ± 2.82
SecondaryChange From Baseline in Impedance

Electrical impedance is a method for body composition assessment. The procedure involves sending a small current through the body and measuring the resistance in ohm. High resistance is associated with smaller amounts of fat-free mass. Smaller resistance is associated with large amounts of fat-free mass.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · ohms
Change From Baseline in Impedance
ohmsMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Change From Baseline in Impedance21.6 ± 77.212.2 ± 54.2
SecondaryChange From Baseline in Body Fat Mass
Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · kg
Change From Baseline in Body Fat Mass
kgMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Change From Baseline in Body Fat Mass3.2 ± 4.12.2 ± 3.4
SecondaryChange in Hip Circumference
Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · cm
Change in Hip Circumference
cmMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Change in Hip Circumference2.5 ± 3.71.8 ± 3.6
SecondaryChange in Waist Circumference
Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · cm
Change in Waist Circumference
cmMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Change in Waist Circumference7.1 ± 4.95.4 ± 4.7
SecondaryChange in Tricep Skinfold
Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · cm
Change in Tricep Skinfold
cmMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Change in Tricep Skinfold1.0 ± 2.61.5 ± 5.4
SecondaryChange in Mid-arm Circumference
Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · cm
Change in Mid-arm Circumference
cmMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Change in Mid-arm Circumference-0.6 ± 11.51.1 ± 1.5
SecondaryChange in Total Energy

Food intake was quantified by the 24-hour recall food diary

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · kcal
Change in Total Energy
kcalMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Change in Total Energy215.9 ± 830.3150.6 ± 1044.1
SecondaryQuality of Life (QoL) Via Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) at Baseline (Day 3) and Week 12 (BACRI)

The BACRI instrument is used to measure the benefit of weight gain treatment provided to anorexic patients on health related quality of life aspects. The scale is composed of 9 subscales (0 to 10 \[worse to better\]). The response was captured on a VAS scale in cm. The total BACRI score is the sum with a minimum score 0=worse and maximum score 90=better. These subscales are: change in weight impacting health; concern about weight; appearance change; change feeling of appearance; change in appetite; enjoy eating; overall feeling; benefit of treatment; and quality of life.

Time frame:
Baseline (Day 3) to Week 12
Reported as:
Mean · cm
Quality of Life (QoL) Via Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) at Baseline (Day 3) and Week 12 (BACRI)
cmMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Baseline (Day 3)52.3 ± 9.3850.1 ± 7.31
Week 1267.6 ± 9.5365.6 ± 14.78
SecondaryAppetite at Baseline (Day 3) and Week 12

Appetite was assessed via visual analogue scale (VAS) as part of the Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) (Question 5 only). The question was "To what extent has your appetite changed since the start of treatment?" The response was captured on a VAS scale in cm with a range from 0 ( "much worse") to 10 ("much better").

Time frame:
Baseline (Day 3) to Week 12
Reported as:
Mean · cm
Appetite at Baseline (Day 3) and Week 12
cmMegestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Baseline Day 36.1 ± 1.815.8 ± 1.16
Week 128.4 ± 1.308.0 ± 2.14

Adverse events

Collected over Approximately 16 weeks (baseline [day 1] through week 12 plus 30-day follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Megestrol Acetate Oral Suspension NanoCrystal Dispersion—14/32 (43.8%)30/32 (93.8%)
Megestrol Acetate Oral Suspension Micronized Formulation—14/31 (45.2%)30/31 (96.8%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventMegestrol Acetate Oral Suspension NanoCrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Blood cortisol abnormalInvestigations6/323/31
Adrenal insufficiencyEndocrine disorders3/324/31
AnaemiaBlood and lymphatic system disorders0/322/31
Cardiac failure congestiveCardiac disorders1/322/31
Adrenal suppressionEndocrine disorders2/322/31
Pulmonary tuberculosisInfections and infestations0/322/31
Blood cortisol decreasedInvestigations2/320/31
AstheniaGeneral disorders0/321/31
Death of unknown causeGeneral disorders0/321/31
Oedema peripheralGeneral disorders0/321/31
Most frequent other events
Showing 10 of 63
Most frequent other events
EventMegestrol Acetate Oral Suspension NanoCrystal DispersionMegestrol Acetate Oral Suspension Micronized Formulation
Blood lactate dehydrogenase increasedInvestigations12/325/31
Red cell distribution width increasedInvestigations9/325/31
CoughRespiratory, thoracic and mediastinal disorders9/326/31
Adrenal insufficiencyEndocrine disorders4/328/31
Mean cell volume increasedInvestigations8/325/31
HeadacheNervous system disorders8/326/31
DyspepsiaGastrointestinal disorders6/322/31
Mean cell haemoglobin increasedInvestigations5/325/31
HypertensionVascular disorders5/325/31
AstheniaGeneral disorders5/320/31

Baseline characteristics

Analysis based on Intend to Treat (ITT) population; all randomized subjects who were dispensed medication and had at least one post-randomization visit.

Age, Continuous
Age, Continuous(years)Megestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized FormulationTotal
Mean37.3 ± 7.3236.3 ± 7.2236.8 ± 7.23
Sex: Female, Male
Sex: Female, Male(Participants)Megestrol Acetate Oral Suspension Nanocrystal DispersionMegestrol Acetate Oral Suspension Micronized FormulationTotal
Female111627
Male211536
08

Study locations

12 sites
  • Drexel University College of Medicine
    Philadelphia, Pennsylvania 19102, United States
  • Victoria Hospital
    Bangalore, Karnataka 560002, India
  • M.S. Ramaiah Medical College and Hospital
    Bangalore, Karnataka 560054, India
  • Kasturba Medical College
    Mangalore, Karnataka 575003, India
  • Ruby Hall Clinic and Grant Medical Foundation
    Pune, Maharashtra 411001, India
  • St Mary's Hospital
    Private Bag, Ashwood 3605, South Africa
  • Quinta-research
    Pellissier, Bloemfontein 9317, South Africa
  • Genclin Corporation, Clinical Trial Centre
    Westdene, Bloemfontein 9301, South Africa
  • 40 Arthur Hobbs Street
    Boksburg, Johannesburg 1466, South Africa
  • 6 Calypso Centre
    Richards Bay, Kwazulu Natal 3900, South Africa
  • Eastmed Hospital
    Eastlynn, Pretoria 0186, South Africa
  • TrialTech Clinical Research
    Hatfield, Pretoria 0001, South Africa
09

References and documents

Publications

  • Wanke C; Gutierrez J; Kristensen A; MacEarchern L. Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States. J Applied Res 2007;7(3):206-216

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Jun 2005 and a completion of Jun 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 10 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2008
First posted
Mar 18, 2008
Start
Dec 2004
Primary completionActual
Jun 2005
CompletionActual
Jun 2005
Results first posted
Apr 20, 2016
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00637572
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Mar 18, 2008
Start date
Dec 2004
Primary completion
Jun 2005
Completion
Jun 2005
Results posted
Apr 20, 2016
Last update
Oct 5, 2017

Study contacts

Jan Fourie, MD
principal investigator · 58 Ann Street, Dundee, KZ-Natal 3000, S. Africa

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion